India Myocardial Infarction Market to reach $1,066.0 million by 2035

India myocardial infarction market was valued at $457.7 million in 2025 and is projected to reach $1,066.0 million by 2035, growing at a CAGR of 8.9% during 2026–2035. The market growth is primarily driven by the rising burden of cardiovascular diseases, increasing adoption of interventional cardiology procedures, and expanding access to advanced cardiac care across Tier-2 and Tier-3 cities in India. A key macro driver influencing the market is the growing prevalence of cardiovascular diseases. According to the World Health Organization (WHO), cardiovascular diseases account for approximately 27% of total deaths in India, making them the leading cause of mortality in the country. Additionally, WHO highlights that nearly 80% of premature heart disease and stroke cases are preventable, yet rising urbanization, sedentary lifestyles, and increasing diabetes prevalence continue to elevate myocardial infarction (MI) incidence. This epidemiological trend directly translates into higher demand for both pharmacological treatments and interventional procedures such as PCI and CABG.

Browse the full report description of “India Myocardial Infarction Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatment, Interventional Procedures, Adjunct & Supportive Care), By Medical Device Type (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, and Others), By End-User (Hospitals, Specialty Centres, ASCs), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/india-myocardial-infarction-market

Recent Developments

• In September 2025, AliveCor launched the Kardia 12L, an AI-powered handheld ECG system in India in 2025, following approval from Central Drugs Standard Control Organisation. The portable 12-lead device is designed for clinical use and can detect 35 cardiac conditions, including myocardial infarction and ischemia, enabling rapid diagnosis at the point of care.

• In February 2024, the Punjab government, in collaboration with Indian Council of Medical Research, launched the Mission AMRIT STEMI program to enable rapid heart attack treatment through a hub-and-spoke healthcare model.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o By Treatment Type
  o By Medical Device Type
  o By End-User

Competitive Landscape – Pfizer Inc., AstraZeneca plc, Novartis AG, Bayer AG, Johnson & Johnson, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

India Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Adjunct & Supportive Care

By Medical Device Type

• Left Ventricular Assist Device
• Pacemaker
• Catheters
• Implantable Cardioverter Defibrillator
• Others

By End-User

• Public Hospitals
• Private Hospitals
• Cardiac Specialty Centers
• Ambulatory Surgical Centers

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/india-myocardial-infarction-market